Proteins and Peptides

03 Dec 2018 Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU
29 Nov 2018 Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP
28 Nov 2018 Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)
28 Nov 2018 Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease
28 Nov 2018 PhaseBio Announces Dosing of First Patient in Phase 2b Clinical Trial of PB1046 in Pulmonary Arterial Hypertension
28 Nov 2018 Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers
28 Nov 2018 Bayer receives EU approval for its hemophilia A treatment Jivi®
27 Nov 2018 Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies
27 Nov 2018 Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
26 Nov 2018 Immune Regulation Announces Positive Results from Phase 1 Clinical Trial of PIN201104
24 Nov 2018 European Commission Approves Pelmeg▼® (pegfilgrastim) as a Biosimilar Treatment to Reduce the Duration of Neutropenia and Incidence of Febrile Neutropenia in Adults Treated with Chemotherapy
23 Nov 2018 Oral semaglutide demonstrates favourable cardiovascular safety profile and significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial
11 Nov 2018 Brooklyn ImmunoTherapeutics Announces Presentation of Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer
09 Nov 2018 Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114
07 Nov 2018 Cancer Targeted Technology Files Investigational New Drug Application for CTT1403, a Novel Radiotherapeutic Drug for Prostate Cancer
07 Nov 2018 New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers
07 Nov 2018 Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
07 Nov 2018 Endo Announces Positive Results from Phase 3 Studies of Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
03 Nov 2018 U.S. FDA Approves UDENYCA™ (pegfilgrastim-cbqv)
29 Oct 2018 Abicipar Phase 3 Data Presented at AAO Conference in Chicago: Potential to be the First Fixed 12-week Anti-VEGF Therapeutic
28 Oct 2018 Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin
25 Oct 2018 Scarless Laboratories Receives FDA Clearance to Initiate Phase I/IIa Trial of SLI-F06 Peptide for Scar Reduction
24 Oct 2018 Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease
23 Oct 2018 Medicenna Presented Insights from the Phase 2b Clinical Trial of MDNA55 at the European Society for Medical Oncology 2018 Congress
22 Oct 2018 amcure Presents First Clinical Data for Lead Compound AMC303 at ESMO 2018 Congress

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top